Drug Database · Clinicians

Timolol

Brands (25) Agua Tim, Elevex, Intramol…Show all

US brand (reference label): Timoptic; not a Philippine-registered brand.

Anti-glaucoma (beta-adrenoreceptor blocker); Anti-glaucoma (beta blocking agent); and others PH FDA category

Rx · Prescription drug28 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 45ac65b3-19f7-4f33-aebf-cadd3daa4bf1, version date April 30, 2022 (Timoptic · Bausch & Lomb Incorporated). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE TIMOPTIC Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Contraindications

CONTRAINDICATIONS TIMOPTIC is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see WARNINGS]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure [see WARNINGS]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION TIMOPTIC Ophthalmic Solution is available in concentrations of 0.25 and 0.5%. The usual starting dose is one drop of TIMOPTIC 0.25% in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) twice a day.

Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTIC. If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s).

Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day. Dosages above one drop of TIMOPTIC 0.5% twice a day generally have not been shown to produce further reduction in intraocular pressure.

If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted. The concomitant use of two topical beta-adrenergic blocking agents is not recommended [see PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents].

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness of timolol maleate ophthalmic solution have been established when administered in pediatric patients aged 2 years and older. Use of timolol maleate ophthalmic solution in these children is supported by evidence from adequate and well controlled studies in children and adults. Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Dosage forms

Philippines

  • Ophthalmic solution: 2.5 mg/mL, 5 mg per mL, 5 mg/mL
  • Opthalmic solution: 5 mg/g, 5 mg/mL
  • Sterile ophthalmic solution: 5 mg/mL
  • Ophthalmic sterile solution: 5 mg/mL
  • W/v) ophthalmic solution: 5 mg/mL (0.5 %

Registered products in the Philippines

28 products registered with the Food and Drug Administration (FDA) Philippines list Timolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products28
Philippine FDA-registered products for Timolol
Package insert
Agua TimTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana Ophthalmics LLPIndia
Agua Visions TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-07
Sep 5, 2029
ElevexTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ambitech Biopharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-04
Sep 5, 2029
IntramolTimolol (as maleate)
5 mg/mL Ophthalmic SolutionWhite LDPE dropper bottle with HDPE tamper evident screw cap and white LDPE dropper x 5 mL (Box of 1's)
Rx
Beximco Pharmaceuticals Ltd.Bangladesh
Sensomed Phils., Inc.Importer: Ambica International Corporation
DRP-9405
Feb 9, 2028
IotimTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)Translucent LDPE Plastic Bottle x 5mL with insert cap assembly comprising of HDPE screw cap over a LDPE nozzle with LDPE dust cover (Box of 1's)
Rx
FDA LimitedIndia
Penta Labs Australia (Philippines)
DRP-7230
Jun 19, 2027
IsupresTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
I-Senz Medical Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-01
Sep 5, 2029
KhrizmololTimolol (as maleate)
5 mg/mL (0.5 % w/v) Ophthalmic Solution (Eye Drops)10 mL -Capacity C White Opaque PP Dropper Bottle with cap x 5 mL (net content) (Box of 1's)
Rx
Merit Organics LimitedIndia
Khriz Pharma Trading, Inc.
DR-XY49716
May 13, 2031
LopresTimolol ( as maleate )
5 mg/mL (0.5% w/v ) Opthalmic Solution (Drops)5mL white translucent Low Density Polyethylene ( LDPE) Blow Fill Seal Container (BFS) with white High Density Polyethylene (HDPE) cap ( Box of 1's )
Rx
Micro Labs. LimitedIndia
Brown & Burk Philippines Inc.
DRP-7281
Aug 3, 2027
LutimolTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL Low Density Polyethylene (LDPE) vial (Box of 1's)
Rx
Axa Parenterals LimitedIndia
Brady Pharma Inc.
DRP-9580
Mar 5, 2031
NoneTimolol Maleate
0.5% w/v Sterile Ophthalmic SolutionWhite LDPE Dropper-tipped Bottle x 5mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
CELSUS PHARMACEUTICALS PHILS., INC.
DR-XY28847
Aug 7, 2028
NoneTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-03
Sep 5, 2029
NoneTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ambicare Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-05
Sep 5, 2029
NormopresTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic Sterile Solution (Eye Drops)5 mL net content in 10 mL LDPE dropper-tipped plastic bottle (Box of 1's)
Rx
EL Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY31154
Aug 2, 2027
OculolTimolol (as maleate)
5 mg/mL (0.5%) Ophthalmic SolutionPlastic Droptainer Bottle x 5 mL (Box of 1's)
Rx
CENTAUR PHARMACEUTICALS PRIVATE LIMITEDIndia
AVANTMED INTERNATIONAL PHARMA INCImporter: STANGEN PHARMACEUTICALS PHILIPPINES INC
DR-XY38755
Nov 18, 2028
OCUPERTimolol Maleate
5 mg/ mL (0.5%w/v) Ophthalmic Solution5 mL LDPE Plastic Bottle with Secondary Box (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Medilife Pharma, Inc.
DRP-233
Jun 21, 2031
OcutimTimolol maleate
5mg/g (0.5 % w/v) Opthalmic SolutionLDPE vial x 5 mL (Box of 1’s)
Rx
East African (India) OverseasIndia
Airlife International Trading Corporation
DRP-18055
Apr 30, 2031
OptaluzTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-02
Sep 5, 2029
OptamolTimolol (As Maleate)
2.5 mg/mL (0.25% w/v) Ophthalmic Solution (Eye Drops)LDPE Plastic container x 5 mL Box of 1's
Rx
Amanta Healthcare Ltd.India
Endure Medical, Inc.
DR-XY36653
Sep 16, 2029
OptimolTimolol ( as maleate)
5 mg / mL (0.5% w/v) Opthalmic Solution (Drops)LDPE Dropper Bottle with Blue Cap x 5 mL (Box of 1's)
Rx
Laboratorios Ashford Lda.China
Marrion Pharma Inc.
DR-XY35195
Dec 3, 2034
OptinovaTimolol (as Maleate)
5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Drops)5 mL HDPE Vial fitted with Screw Cap (Box of 1's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Medinova Pharmaceutical Inc.
DRP-11804
May 6, 2027
TimabakTimolol Maleate
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL LDPE Bottle with HDPE Cap (Box of 1's)
Rx
ExcelvisionFrance
STADA Philippines Inc.Trader: Laboratoires Thea
DR-XY37200
Dec 10, 2029
TimoCareTimolol Maleate
5 mg/ mL (0.5% w/v) Ophthalmic Solution5 mL LDPE Plastic Bottle with Secondary Box (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Rizal
Sensorycare Pharma Co.Trader: Medilife Pharma, Inc.
DRP-233-03
Jun 21, 2031
Timol-PTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ophtha Pharma Traders Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499-06
Sep 5, 2029
Timolet ODTimolol (as maleate)
5 mg/mL (0.5% w/v) Sterile Ophthalmic Solution (Drops)5 mL LDPE sterile dropper bottle, plugged with 13 mm. LDPE sterile plug and capped with 13 mm white, mm opaque HDPE pilfer proof sterile cap for dropper bottle (Box of 1's)
Rx
Sun Pharmaceutical Medicare LimitedIndia
Sun Pharma Philippines, Inc.
DRP-11016
Jan 3, 2032
TimophilTimolol (as maleate)
5mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)
Rx
Skymap Pharmaceuticals Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-17726
Feb 23, 2031
TimoptolTimolol maleate
5 mg/mL (0.5% w/v)LDPE Type-6 container x 5 mL (Box of 1's)
Rx
Santen Pharmaceutical Co., Ltd. (Noto Plant)Japan
Importer: Santen Philippines Inc.
DR-X6980
Aug 2, 2031
TimosaphTimolol (As Maleate)
5 mg/mL (0.5% w/v) Ophthalmic Solution (Eye Drops)White HDPE Dropper Bottle with Close nozzle and single pilfer proof ring Cap x 5 mL (net content) (Box of 1's)
Rx
Health Biotech Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd
DRP-13632
Mar 21, 2028
TimostalTimolol (as Maleate)
5 mg/mL (0.5% w/v) Ophthalmic SolutionOpaque LDPE Bottle x 10 mL (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ophthamed Pharma Corp.,Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-5499
Sep 5, 2029
TomololTimolol (As Maleate)
5 mg per mL Ophthalmic Solution10 mL PET Bottle with Tamper-Evident Cap (Box of 1's)
Rx
Joint Stock Company "Farmak"Ukraine
Suhitas Pharmaceuticals, Inc.
DRP-12880
Oct 24, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS As with many topically applied ophthalmic drugs, this drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see CONTRAINDICATIONS].

Cardiac Failure Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure. In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure.

At the first sign or symptom of cardiac failure, TIMOPTIC should be discontinued. Obstructive Pulmonary Disease Patients with chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which TIMOPTIC is contraindicated [see CONTRAINDICATIONS]) should, in general, not receive beta-blockers, including TIMOPTIC.

Major Surgery The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures.

Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents.

Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia. Thyrotoxicosis Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Although TIMOPTIC used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with TIMOPTIC and epinephrine has been reported occasionally. Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and TIMOPTIC should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.

The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium antagonists: Caution should be used in the coadministration of beta-adrenergic blocking agents, such as TIMOPTIC, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension.

In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Digitalis and calcium antagonists: The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. CYP2D6 inhibitors: Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.

Clonidine: Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic timolol maleate. Injectable epinephrine: [see PRECAUTIONS, General, Anaphylaxis].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

CYP2D6 inhibitors: Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The most frequently reported adverse experiences have been burning and stinging upon instillation (approximately one in eight patients). The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations: Body as a Whole Headache, asthenia/fatigue, and chest pain.

Cardiovascular Bradycardia, arrhythmia, hypotension, hypertension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure, worsening of angina pectoris, palpitation, cardiac arrest, pulmonary edema, edema, claudication, Raynaud's phenomenon, and cold hands and feet. Digestive Nausea, diarrhea, dyspepsia, anorexia, and dry mouth.

Immunologic Systemic lupus erythematosus. Nervous System/Psychiatric Dizziness, increase in signs and symptoms of myasthenia gravis, paresthesia, somnolence, insomnia, nightmares, behavioral changes and psychic disturbances including depression, confusion, hallucinations, anxiety, disorientation, nervousness, and memory loss.

Skin Alopecia and psoriasiform rash or exacerbation of psoriasis. Hypersensitivity Signs and symptoms of systemic allergic reactions, including anaphylaxis, angioedema, urticaria, and localized and generalized rash. Respiratory Bronchospasm (predominantly in patients with preexisting bronchospastic disease), respiratory failure, dyspnea, nasal congestion, cough and upper respiratory infections.

Endocrine Masked symptoms of hypoglycemia in diabetic patients [see WARNINGS]. Special Senses Signs and symptoms of ocular irritation including conjunctivitis, blepharitis, keratitis, ocular pain, discharge (e.g., crusting), foreign body sensation, itching and tearing, and dry eyes; ptosis; decreased corneal sensitivity; cystoid macular edema; visual disturbances including refractive changes and diplopia; pseudopemphigoid; choroidal detachment following filtration surgery [see PRECAUTIONS, General]; and tinnitus.

Urogenital Retroperitoneal fibrosis, decreased libido, impotence, and Peyronie's disease. The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous rash, fever combined with aching and sore throat, laryngospasm with respiratory distress; Body as a Whole: Extremity pain, decreased exercise tolerance, weight loss; Cardiovascular: Worsening of arterial insufficiency, vasodilatation; Digestive: Gastrointestinal pain, hepatomegaly, vomiting, mesenteric arterial thrombosis, ischemic colitis; Hematologic: Nonthrombocytopenic purpura; thrombocytopenic purpura, agranulocytosis; Endocrine: Hyperglycemia, hypoglycemia; Skin: Pruritus, skin irritation, increased pigmentation, sweating; Musculoskeletal: Arthralgia; Nervous System/Psychiatric: Vertigo, local weakness, diminished concentration, reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics; Respiratory: Rales, bronchial obstruction; Urogenital: Urination difficulties.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects - Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring.

Doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

There are no adequate and well-controlled studies in pregnant women. TIMOPTIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from TIMOPTIC in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Mechanism of action

Mechanism of Action Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease.

In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity.

Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous. TIMOPTIC Ophthalmic Solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss.

The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. The onset of reduction in intraocular pressure following administration of TIMOPTIC can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose.

Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC is well maintained. The precise mechanism of the ocular hypotensive action of TIMOPTIC is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation.

However, in some studies a slight increase in outflow facility was also observed.

US FDA label

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

Pharmacokinetics In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Timolol Eye Drops 0.5%, 5 mL Bottle₱210.00–₱360.00Reference ₱281.50per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Timolol (as maleate)
PNF listingEye Drops Solution: 0.5%, 5 mL bottle
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Timoptic · Bausch & Lomb Incorporated [US FDA-approved label, version 11, April 30, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45ac65b3-19f7-4f33-aebf-cadd3daa4bf1
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .